Randomized Trial Comparing Rituximab Against Mycophenolate Mofetil in Children Wtih Refractory Nephrotic Syndrome
Status:
Terminated
Trial end date:
2017-01-18
Target enrollment:
Participant gender:
Summary
We hypothesize that the anti-CD20 monoclonal antibody Rituximab will be more effective than
MMF in maintaining remission in children with frequent relapsing or steroid dependent
nephrotic syndrome who have had one relapse while receiving MMF.
We will conduct a randomized study comparing two Rituximab infusions and continued MMF
treatment. We plan to enroll 64 to have a comparater group of 58 (29 in each arm).
Phase:
Phase 3
Details
Lead Sponsor:
Nationwide Children's Hospital
Collaborators:
Children's Healthcare of Atlanta Emory University Genentech, Inc. The NephCure Foundation